About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

STELLA PHARMA CORPORATION(4888) Summary

4888
TSE Growth
STELLA PHARMA CORPORATION
315
JPY
-13
(-3.96%)
Apr 16, 1:41 pm JST
2.20
USD
Apr 16, 12:41 am EDT
Result
PTS
outside of trading hours
314.8
Apr 16, 1:38 pm JST
Summary Chart Historical News Financial Result
PER
PBR
3.60
Yield
ー%
Margin Trading Ratio
Stock Price
Apr 16, 2025
Opening Apr 16, 9:00 am
325 JPY 2.27 USD
Previous Close Apr 15
328 JPY 2.29 USD
High Apr 16, 9:00 am
327 JPY 2.28 USD
Low Apr 16, 1:02 pm
314 JPY 2.20 USD
Volume
162,000
Trading Value
0.05B JPY 0.36M USD
VWAP
320.44 JPY 2.25 USD
Minimum Trading Value
31,500 JPY 220 USD
Market Cap
0.01T JPY 0.08B USD
Number of Trades
258
Liquidity & Number of Trades
As of Apr 16, 2025
Liquidity
Slightly High
1-Year Average
567
1-Year High Sep 3, 2024
8,285
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 11, 2025 0 1,608,000
Apr 4, 2025 0 1,918,400
Mar 28, 2025 0 2,247,600
Mar 21, 2025 0 2,141,900
Mar 14, 2025 0 2,208,200
Company Profile
STELLA PHARMA CORPORATION is a subsidiary of Stella Chemifa. The company develops, manufactures, and sells boron-based pharmaceuticals for cancer radiotherapy.
Sector
Pharmaceuticals
STELLA PHARMA CORPORATION is a biotech venture company within the Stella Chemifa group. It specializes in the development, manufacturing, and sales of "Steboronine," a boron-based pharmaceutical for cancer radiotherapy. The company has obtained the world's first approval for a drug used in Boron Neutron Capture Therapy (BNCT). Steboronine has been launched in Japan for the treatment of unresectable locally advanced or locally recurrent head and neck cancer. Clinical trials are currently underway to expand its applications to recurrent malignant glioma and recurrent high-grade meningioma. Leveraging its strength in high-purity boron-10 enrichment technology, STELLA PHARMA CORPORATION aims to expand its business both domestically and internationally.